{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:46:22Z","timestamp":1787071582679,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Gall bladder (GB) is a rare site of neuroendocrine carcinoma (NEC). Gallbladder neuroendocrine carcinoma (GB-NEC) comprises only ~0.2% of all gastrointestinal NECs and 4% of all GB cancers. In the published literature, only a few isolated case reports and rare case series of GB-NEC are available. Worldwide, the largest series of GB-NEC reported is of 19 cases from India. In this study, we present clinicopathological features of 56 cases of GB-NEC diagnosed in a tertiary care cancer hospital of northern part of India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To study the clinicopathological and immunohistochemical features of GB-NEC from the archives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective data of GB-NEC, diagnosed over 53 months were collected from institutional electronic medical records. Hematoxylin and eosin (H and E) stained slides and corresponding immunohistochemistry slides were reviewed and included in the study. Data was compiled and basic statistical analysis was done.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      GB-NEC constituted 3.19% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 56\/1752) of all GB carcinomas. Histological types of GB-NEC were: small cell NEC (96.4%, n = 54), large cell NEC (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 1), and NEC with sarcomatous differentiation (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 1). The diagnosis was ratified by use of combination of two neuroendocrine markers in varying combination comprising of Synaptophysin, chromogranin and INSMI1. Ki-67 index ranged from 50%\u201380% in 6 cases and more than 80% in 10 cases where count of mitotic figures was limited by extensive areas of necrosis. Follow-up of 6\u20138 months was available for 22 patients out of which 21 cases were living with disease. Twenty-two patients were treated with palliative chemotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>GB-NEC is a rare and aggressive malignancy with poor prognosis due to advanced clinical stage of presentation and limited availability of treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1366_24","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:00:18Z","timestamp":1758906018000},"page":"1052-1058","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Neuroendocrine carcinoma of the gall bladder: A clinicopathological report of 56 Cases from a tertiary care cancer center in North India"],"prefix":"10.4103","volume":"21","author":[{"given":"Paramita R.","family":"Pal","sequence":"first","affiliation":[{"name":"Department of Oncopathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC), Tata Memorial Centre (TMC) Varanasi, Homi Bhabha National Institute (HBNI), Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramita","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC), Tata Memorial Centre (TMC) Varanasi, Homi Bhabha National Institute (HBNI), Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikant C. U.","family":"Patne","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC), Tata Memorial Centre (TMC) Varanasi, Homi Bhabha National Institute (HBNI), Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachariah","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC), Tata Memorial Centre (TMC) Varanasi, Homi Bhabha National Institute (HBNI), Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipsita","family":"Dhal","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC), Tata Memorial Centre (TMC) Varanasi, Homi Bhabha National Institute (HBNI), Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Haiyat","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre (MPMMCC), Tata Memorial Centre (TMC) Varanasi, Homi Bhabha National Institute (HBNI), Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"R1-20250929","first-page":"e1755","article-title":"Neuroendocrine tumor of the cystic duct:A rare and incidental diagnosis","volume":"9","author":"Ayub","year":"2017","journal-title":"Cureus"},{"key":"R2-20250929","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1245\/s10434-019-07440-6","article-title":"Primary gallbladder neuroendocrine tumors:Insights into a rare histology using a large national database","volume":"26","author":"Ayabe","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"R3-20250929","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d:Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-20250929","first-page":"471","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R5-20250929","doi-asserted-by":"crossref","first-page":"8212","DOI":"10.12998\/wjcc.v10.i23.8212","article-title":"Gallbladder neuroendocrine carcinoma diagnosis, treatment and prognosis based on the SEER database:A literature review","volume":"10","author":"Cai","year":"2022","journal-title":"World J Clin Cases"},{"key":"R6-20250929","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12029-015-9745-9","article-title":"Neuroendocrine carcinoma of gall bladder:A series of 19 cases with review of literature","volume":"46","author":"Kamboj","year":"2015","journal-title":"J Gastrointest Cancer"},{"key":"R8-20250929","first-page":"182","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system"},{"key":"R9-20250929","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00000478-200105000-00005","article-title":"Small cell carcinoma of the gallbladder:A clinicopathologic, immunohistochemical, and molecular pathology study of 12 cases","volume":"25","author":"Maitra","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"R10-20250929","first-page":"1064","article-title":"Neuroendocrine tumors of the gallbladder:Twelve cases in a single institution","volume":"57","author":"Lee","year":"2010","journal-title":"Hepato-Gastroenterology"},{"key":"R11-20250929","first-page":"8218","article-title":"Gallbladder neuroendocrine carcinoma:Report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma","volume":"8","author":"Chen","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"R12-20250929","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2147\/CMAR.S227501","article-title":"Clinical analysis of 15 cases of gallbladder neuroendocrine carcinoma and comparison with gallbladder adenocarcinoma using a propensity score matching","volume":"12","author":"Yan","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R13-20250929","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40792-016-0200-3","article-title":"Gallbladder small cell carcinoma:A case report and literature review","volume":"2","author":"Adachi","year":"2016","journal-title":"Surg Case Rep"},{"key":"R14-20250929","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40001-019-0363-z","article-title":"Neuroendocrine carcinoma of gallbladder:A case series and literature review","volume":"24","author":"Liu","year":"2019","journal-title":"Eur J Med Res"},{"key":"R15-20250929","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/MCG.0b013e3181d7a6d4","article-title":"Neuroendocrine tumors of the gallbladder:An evaluation and reassessment of management strategy","volume":"44","author":"Eltawil","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"R17-20250929","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anndiagpath.2007.08.003","article-title":"Paraneoplastic sensory neuropathy associated with small cell carcinoma of the gallbladder","volume":"13","author":"Uribe-Uribe","year":"2009","journal-title":"Ann Diagn Pathol"},{"key":"R18-20250929","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4174\/jkss.2012.82.1.54","article-title":"Primary carcinosarcoma of the gallbladder","volume":"82","author":"Park","year":"2012","journal-title":"J Korean Surg Soc"},{"key":"R19-20250929","first-page":"75","article-title":"Prognostic significance of race and tumor size in carcinosarcoma of gallbladder:A meta-analysis of 68 cases","volume":"1","author":"Zhang","year":"2008","journal-title":"Int J Clin Exp Pathol"},{"key":"R20-20250929","first-page":"946835","article-title":"Distal humerus as delayed site of metastasis from small cell carcinoma of gallbladder","volume":"2013","author":"Tunio","year":"2013","journal-title":"Case Rep Gastrointest Med"},{"key":"R21-20250929","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"(Suppl 5)","key":"R22-20250929","doi-asserted-by":"crossref","first-page":"v223","DOI":"10.1093\/annonc\/mdq192","article-title":"Neuroendocrine gastroenteropancreatic tumours:ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Oberg","year":"2010","journal-title":"Ann Oncol"},{"key":"R23-20250929","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jjco\/hyp173","article-title":"Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas","volume":"40","author":"Iwasa","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"R24-20250929","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10555-023-10121-2","article-title":"Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma","volume":"42","author":"Ooki","year":"2023","journal-title":"Cancer Metastasis Rev"},{"key":"R25-20250929","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/2159-8290.CD-21-0669","article-title":"Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system","volume":"12","author":"Yachida","year":"2022","journal-title":"Cancer Discov"},{"key":"R26-20250929","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1158\/1078-0432.CCR-21-3058","article-title":"Expanding therapeutic opportunities for extrapulmonary neuroendocrine carcinoma","volume":"28","author":"Frizziero","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R27-20250929","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"R28-20250929","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/0008-5472.CAN-21-2964","article-title":"Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy","volume":"82","author":"Quintanal-Villalonga","year":"2022","journal-title":"Cancer Res"},{"key":"R29-20250929","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.humpath.2015.08.006","article-title":"Molecular characteristics of colorectal neuroendocrine carcinoma;similarities with adenocarcinoma rather than neuroendocrine tumor","volume":"46","author":"Takizawa","year":"2015","journal-title":"Hum Pathol"},{"key":"R30-20250929","doi-asserted-by":"crossref","first-page":"e14841","DOI":"10.15252\/emmm.202114841","article-title":"Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells","volume":"14","author":"Costanzo","year":"2022","journal-title":"EMBO Mol Med"},{"key":"R31-20250929","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging concepts for immune checkpoint blockade-based combination therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1366_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:48:49Z","timestamp":1787068129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1366_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1366_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-07-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}